- PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER
-
The invention provides compounds of the formula (1): or a salt or tautomer thereof wherein A, R1, R2, R3, R4, R5 and R6 are as defined herein. The compounds are inhibitors of Wee1 and/or PLK1 kinase and are envisaged to be useful in the treatment of cancers.
- -
-
-
- Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity
-
A series of chemical optimizations guided by in vitro affinity at a histamine H3 receptor (H3R), physicochemical properties, and pharmacokinetics in rats resulted in identification of N-[4-(1-cyclobutyl-piperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (17v, SUVN-G3031) as a clinical candidate. Compound 17v is a potent (hH3R Ki = 8.73 nM) inverse agonist at H3R with selectivity over other 70 targets, Compound 17v has adequate oral exposures and favorable elimination half-lives both in rats and dogs. It demonstrated high receptor occupancy and marked wake-promoting effects with decreased rapid-eye-movement sleep in orexin-B saporin lesioned rats supporting its potential therapeutic utility in treating human sleep disorders. It had no effect on the locomotor activity at doses several fold higher than its efficacious dose. It is devoid of hERG and phospholipidosis issues. Phase-1 evaluation for safety, tolerability, and pharmacokinetics, and long-term safety studies in animals have been successfully completed without any concern for further development.
- Nirogi, Ramakrishna,Shinde, Anil,Mohammed, Abdul Rasheed,Badange, Rajesh Kumar,Reballi, Veena,Bandyala, Thrinath Reddy,Saraf, Sangram Keshari,Bojja, Kumar,Manchineella, Sravanthi,Achanta, Pramod Kumar,Kandukuri, Kiran Kumar,Subramanian, Ramkumar,Benade, Vijay,Palacharla, Raghava Choudary,Jayarajan, Pradeep,Pandey, Santoshkumar,Jasti, Venkat
-
p. 1203 - 1217
(2019/02/24)
-
- Catalytic Selective Oxidative Coupling of Secondary N-Alkylanilines: An Approach to Azoxyarene
-
Azoxyarenes are among important scaffolds in organic molecules. Direct oxidative coupling of primary anilines provides a concise fashion to construct them. However, whether these scaffolds can be prepared from secondary N-alkylanilines is not well explored. Here, we present a catalytic selective oxidative coupling of secondary N-alkylaniline to afford azoxyarene with tungsten catalyst under mild conditions. In addition, azoxy can be viewed as a bioisostere of alkene and amide. Several "azoxyarene analogues" of the corresponding bioactive alkenes and amides showed comparable promising anticancer activities.
- Ke, Lei,Zhu, Guirong,Qian, Hui,Xiang, Guangya,Chen, Qin,Chen, Zhilong
-
p. 4008 - 4013
(2019/06/04)
-
- SUBSTITUTED HYDANTOIN AND THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS
-
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the antagonism of one or more androgen receptor types. Such compounds are represented by Formula (I), wherein R1, R2a, R,2b,Z
- -
-
-
- 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
-
The present invention relates to novel compounds having histone deacetylase 6 (HDAC6) in-hibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present invention have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and be-havioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, de? formations and chromosomal abnormalities.
- -
-
-
- Straightforward synthesis of a novel ring-fused pyrazole-lactam and in vitro cytotoxic activity on cancer cell lines
-
In this paper a straightforward synthesis of a novel pyrazole derivative is reported. Prominent feature of this synthetic process is a 1,3-Dipolar Cycloaddition of a suitable nitrile imine with an activated α,β-unsaturated lactam to afford directly and re
- Bertuzzi,Locatelli,Colecchia,Calandro,Bonini,Chandanshive,Mazzanti,Zani,Chiariello,Comes Franchini
-
-
- PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS
-
The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
- -
-
-
- VEGFR3 INHIBITORS
-
This invention relates to compounds of the formula (I). The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphanglogenesis.
- -
-
-
- DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS
-
Provided herein are compounds of the formula (I) as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
- -
-
-
- Cinnamyl derivatives: Synthesis and factor Xa (FXa) inhibitory activities
-
To develop a potent and oral anticoagulant, a series of compounds with cinnamyl moiety was synthesized and their factor Xa (FXa) inhibitory activities were examined. As a result, some cinnamyl derivatives showed potent FXa inhibitory activities in vitro. Among them, compounds with substituent at the 3-position on the central benzene ring represented by (N-{4-[1-(acetimidoyl) piperidin-4-yloxy]-3-chlorophenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl] sulfamoyl)acetic acid dihydrochloride (45b) and (N-{4-[1-(acetimidoyl)piperidin- 4-yloxy]-3-carbamoylphenyl}-N-[(E)-3-(3-amidinophenyl)-2-propenyl]sulfamoyl) acetic acid dihydrochloride (45j) exhibited potent FXa inhibitory activities with IC50 values of less than 10 nM in vitro. These compounds also showed potent anticoagulant activities both in vitro and ex vivo. Furthermore, these compounds exhibited no lethal toxicity (30 mg/kg, i.v.).
- Noguchi, Tetsuji,Tanaka, Naoki,Nishimata, Toyoki,Goto, Riki,Hayakawa, Miho,Sugidachi, Atsuhiro,Ogawa, Taketoshi,Asai, Fumitoshi,Fujimoto, Koichi
-
experimental part
p. 758 - 770
(2009/05/31)
-
- Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists
-
Disclosed are compounds of the formula or a pharmaceutically acceptable salt or solvate thereof, wherein: M is CH or N; U and W are each CH, or one of U and W is CH and the other is N; X is a bond, alkylene, —C(O)—, —C(N—OR5)—, —C(N—OR5)—CH(R6)—, —CH(R6)—C(N—OR5)—, —O—, —OCH2—, —CH2O— or —S(O)0-2—; Y is —O—, —(CH2)2—, —C(═O)—, —C(═NOR7)— or —SO0-2—; Z is a bond, optionally substituted alkylene or alkylene interrupted by a heteroatom or heterocyclic group; R1 is optionally substituted alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heterocycloalkyl, or benzimidazolyl or a derivative thereof; R2 is optionally substituted alkyl, alkenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl or heterocycloalkyl; and the remaining variables are as defined in the specification; compositions and methods for treating an allergy-induced airway response, congestion, diabetes, obesity, an obesity-related disorder, metabolic syndrome and a cognition deficit disorder using said compounds, alone or in combination with other agents.
- -
-
Page/Page column 20-21
(2010/11/27)
-
- BISARYLUREA DERIVATIVES
-
The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
- -
-
Page/Page column 203-204
(2010/02/13)
-
- UREIDO-PYRAZOLE DERIVATIVES AND THEIR USE AS KINASE INHIBITORS
-
The present invention provides kinase inhibitors of Formula I: wherein:R1 is hydrogen, methyl, or tolyl;W is piperidinyl, napthyl, or phenyl optionally substituted with halo;X is a bond, -CH2-, -O-(CH2)n-, -O-,
- -
-
Page/Page column 11
(2008/06/13)
-
- BENZAMIDINE DERIVATIVE
-
Compounds of general formula (1) and pharmacologically acceptable salts thereof: ???[wherein ??????R1 represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; ??????R2 represents a hydrogen atom or a halogen atom; ??????R3 represents a hydrogen atom, an alkyl group which may be substituted, an aralkyl group, an alkylcarbonyl group which may be substituted, an alkylsulfonyl group which may be substituted or the like; ??????each of R4 and R5 represents a hydrogen atom, a halogen atom, an alkyl group which may be substituted, a carbamoyl group or the like; ??????R6 represents a heterocycle or the like; ??????each of R7 and R8 represents a hydrogen atom, an alkyl group or the like; ??????n represents 0, 1 or 2] ???exhibit excellent activated blood coagulation factor X inhibitory activity and are useful for the prevention or treatment of blood coagulation-related diseases.
- -
-
-
- Structure-activity relationships of potent and selective factor Xa inhibitors: benzimidazole derivatives with the side chain oriented to the prime site of factor Xa.
-
A series of benzimidazole derivatives with the side chain on the nitrogen atom oriented to the prime site of factor Xa (FXa) were designed and synthesized. Compounds with substituted aminocarbonylmethyl groups as the side chain showed potent FXa inhibitor
- Ueno, Hiroshi,Katoh, Susumu,Yokota, Katsuyuki,Hoshi, Jun-ichi,Hayashi, Mikio,Uchida, Itsuo,Aisaka, Kazuo,Hase, Yasunori,Cho, Hidetsura
-
p. 4281 - 4286
(2007/10/03)
-
- BENZAMIDINE DERIVATIVES
-
Benzamidine derivatives of formula (I) or pharmaceutically acceptable salts thereof exhibit excellent inhibitory activity against factor Xa and are useful for treating or preventing blood coagulation disorders: wherein R 1represents a hydrogen atom, a halogen atom, an alkyl group or a hydroxyl group; R 2represents a hydrogen atom, a halogen atom or an alkyl group, R 3represents a hydrogen atom, an optionally substituted alkyl group, an aralkyl group, an optionally substituted alkanoyl group or an optionally substituted alkylsulfonyl group, R 4and R 5 are the same as or different from each other and each represent a hydrogen atom, a halogen atom, an optionally substituted alkyl group, an alkoxy group, a carboxyl group, an alkoxycarbonyl group or an optionally substituted carbamoyl group, and R 6represents a substituted pyrrolidine group or substituted piperidine group.
- -
-
-
- Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors
-
A series of benzoxazinone derivatives was designed and synthesized as factor Xa inhibitors. We demonstrated that the naphthyl moiety in the aniline-based compounds 1 and 2 can be replaced with benzene-fused heterobicycles and biaryls to give factor Xa inh
- Huang, Wenrong,Zhang, Penglie,Zuckett, Jingmei F.,Wang, Lingyan,Woolfrey, John,Song, Yonghong,Jia, Zhaozhong J.,Clizbe, Lane A.,Su, Ting,Tran, Katherine,Huang, Brian,Wong, Paul,Sinha, Uma,Park, Gary,Reed, Andrea,Malinowski, John,Hollenbach, Stanley J.,Scarborough, Robert M.,Zhu, Bing-Yan
-
p. 561 - 566
(2007/10/03)
-
- Amidine compounds
-
A compound of the formula [I] wherein R1, R2and R3are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the presen
- -
-
-
- Design and synthesis of aminophenol-based factor Xa inhibitors
-
A novel potent and selective aminophenol scaffold for fXa inhibitors was developed from a previously reported benzimidazole-based naphthylamidine template. The aminophenol template is more synthetically accessible than the benzimidazole template, which si
- Wu, Shung,Guilford, William J,Chou, Yuo-Ling,Griedel, Brian D,Liang, Amy,Sakata, Steve,Shaw, Kenneth J.,Trinh, Lan,Xu, Wei,Zhao, Zuchun,Morrissey, Michael M.
-
p. 1307 - 1310
(2007/10/03)
-
- The discovery of YM-60828: a potent, selective and orally-bioavailable factor Xa inhibitor.
-
Since Factor Xa (FXa) is well known to play a central role in thrombosis and hemostasis, inhibition of FXa is an attractive target for antithrombotic strategies. As a part of our investigation of a non-peptide, orally available FXa inhibitor, we found tha
- Hirayama, Fukushi,Koshio, Hiroyuki,Katayama, Naoko,Kurihara, Hiroyuki,Taniuchi, Yuta,Sato, Kazuo,Hisamichi, Nami,Sakai-Moritani, Yumiko,Kawasaki, Tomihisa,Matsumoto, Yuzo,Yanagisawa, Isao
-
p. 1509 - 1523
(2007/10/03)
-
- Benzenamine derivatives as anti-coagulants
-
This invention is directed to benzenamine derivatives of formula (I): wherein A, W, m, n, R1, R2, R3, R4, R5and R6are defined herein. These compounds are useful as anti-coagulants.
- -
-
Page column 43
(2010/02/05)
-
- BENZAMIDINE DERIVATIVES
-
Benzamidine derivatives of the following formulae or analogs thereof, i. e., pharmaceutically acceptable salts thereof, are provided. These compounds or salts thereof have a blood-coagulation inhibiting effect based on an excellent effect of inhibiting the action of activated blood coagulation factor X, and they are useful as anticoagulants.
- -
-
-
- 3-AMIDINOANILINE DERIVATIVES, ACTIVATED BLOOD COAGULATION FACTOR X INHIBITORS, AND INTERMEDIATES FOR PRODUCING BOTH
-
The present invention relates to a 3-amidinoaniline derivative represented by the general formula: wherein R represents a hydrogen atom, a lower alkyl group, a lower alkenyl group etc.; R1 represents a hydrogen atom, a hydroxy group, a lower alkyl group etc.; Y represents a single bond or an oxygen atom; and R2 represents a lower alkyl group or a group represented by the general formula: wherein n represents 1 or 2; and T represents a hydrogen atom or a group represented by the general formula:-C(=NH)-W wherein W represents a lower alkyl group; or a pharmaceutically acceptable salt thereof, which has a potent and selective activated blood coagulation factor X inhibitory activity, and an intermediate for producing both.
- -
-
-